MX2009006630A - Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. - Google Patents
Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.Info
- Publication number
- MX2009006630A MX2009006630A MX2009006630A MX2009006630A MX2009006630A MX 2009006630 A MX2009006630 A MX 2009006630A MX 2009006630 A MX2009006630 A MX 2009006630A MX 2009006630 A MX2009006630 A MX 2009006630A MX 2009006630 A MX2009006630 A MX 2009006630A
- Authority
- MX
- Mexico
- Prior art keywords
- aldosterone
- imidazolyl
- beta
- hydroxylase inhibitors
- tetrahydroquinoline derivatives
- Prior art date
Links
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- LELSSYDOWXMCEK-UHFFFAOYSA-N 4-(1h-imidazol-2-yl)-1,2,3,4-tetrahydroquinoline Chemical class C12=CC=CC=C2NCCC1C1=NC=CN1 LELSSYDOWXMCEK-UHFFFAOYSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 title 1
- 229960002478 aldosterone Drugs 0.000 title 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract 2
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 abstract 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de la fórmula (I) (ver fórmula (I)) este compuesto es inhibidor de la sintasa de aldosterona y/o de la 11beta-hidroxiIasa (CYP11B1), y por consiguiente, se puede emplear para el tratamiento de un trastorno o enfermedad mediada por la sintasa de aldosterona y/o CYP11B1. Finalmente, la presente invención también proporciona una composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87049706P | 2006-12-18 | 2006-12-18 | |
| PCT/US2007/087522 WO2008076860A1 (en) | 2006-12-18 | 2007-12-14 | 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006630A true MX2009006630A (es) | 2009-06-30 |
Family
ID=39309674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006630A MX2009006630A (es) | 2006-12-18 | 2007-12-14 | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8143278B2 (es) |
| EP (1) | EP2121652A1 (es) |
| JP (1) | JP2010513558A (es) |
| KR (1) | KR20090090395A (es) |
| CN (1) | CN101605776A (es) |
| AU (1) | AU2007333902A1 (es) |
| BR (1) | BRPI0720383A2 (es) |
| CA (1) | CA2673119A1 (es) |
| EA (1) | EA200900812A1 (es) |
| MX (1) | MX2009006630A (es) |
| WO (1) | WO2008076860A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2094680A2 (en) * | 2006-12-18 | 2009-09-02 | Novartis AG | Imidazoles as aldosterone synthase inhibitors |
| TW201006823A (en) * | 2008-07-14 | 2010-02-16 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| LT2523731T (lt) * | 2010-01-14 | 2019-02-11 | Novartis Ag | Antinksčių hormoną modifikuojančio agento panaudojimas |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
| JP6574705B2 (ja) | 2013-03-08 | 2019-09-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルドステロン合成酵素（ｃｙｐ１１ｂ２又はｃｙｐ１１ｂ１）阻害剤としての新規ジヒドロキノリン−２−オン誘導体 |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| TW201536814A (zh) | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| JP2015110563A (ja) * | 2013-11-08 | 2015-06-18 | 日本メジフィジックス株式会社 | アルドステロン合成酵素阻害剤 |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| CN104774884A (zh) * | 2015-04-14 | 2015-07-15 | 遵义医学院 | 一种具有光学活性的组合物 |
| CN104774177A (zh) * | 2015-04-14 | 2015-07-15 | 遵义医学院 | 一种具有光学活性的多环苄醇衍生物 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| CN113166204B (zh) | 2018-11-27 | 2025-01-28 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| CN112079826B (zh) * | 2020-09-17 | 2022-07-29 | 广州中医药大学(广州中医药研究院) | 一类甾体合成酶抑制剂及其治疗应用 |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8320184D0 (en) * | 1983-07-27 | 1983-09-01 | Beecham Group Plc | Compounds |
| NZ219311A (en) * | 1986-02-27 | 1989-04-26 | Janssen Pharmaceutica Nv | Imidazoles and herbicidal compositions |
| EP1325914A4 (en) * | 2000-09-14 | 2004-11-17 | Kaken Pharma Co Ltd | TETRAHYDROQUINOLINE COMPOUNDS |
| DE102004035322A1 (de) * | 2004-07-21 | 2006-02-16 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
| CN101410389A (zh) * | 2006-03-29 | 2009-04-15 | 诺瓦提斯公司 | 有机化合物 |
| EP2094680A2 (en) | 2006-12-18 | 2009-09-02 | Novartis AG | Imidazoles as aldosterone synthase inhibitors |
| KR20090094374A (ko) | 2006-12-18 | 2009-09-04 | 노파르티스 아게 | 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도 |
-
2007
- 2007-12-14 JP JP2009543095A patent/JP2010513558A/ja active Pending
- 2007-12-14 WO PCT/US2007/087522 patent/WO2008076860A1/en not_active Ceased
- 2007-12-14 EA EA200900812A patent/EA200900812A1/ru unknown
- 2007-12-14 AU AU2007333902A patent/AU2007333902A1/en not_active Abandoned
- 2007-12-14 EP EP07869266A patent/EP2121652A1/en not_active Withdrawn
- 2007-12-14 MX MX2009006630A patent/MX2009006630A/es not_active Application Discontinuation
- 2007-12-14 KR KR1020097014925A patent/KR20090090395A/ko not_active Withdrawn
- 2007-12-14 BR BRPI0720383-7A patent/BRPI0720383A2/pt not_active IP Right Cessation
- 2007-12-14 US US12/519,703 patent/US8143278B2/en not_active Expired - Fee Related
- 2007-12-14 CN CNA2007800511861A patent/CN101605776A/zh active Pending
- 2007-12-14 CA CA002673119A patent/CA2673119A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA200900812A1 (ru) | 2009-12-30 |
| CN101605776A (zh) | 2009-12-16 |
| US8143278B2 (en) | 2012-03-27 |
| BRPI0720383A2 (pt) | 2015-06-16 |
| WO2008076860A1 (en) | 2008-06-26 |
| EP2121652A1 (en) | 2009-11-25 |
| AU2007333902A1 (en) | 2008-06-26 |
| CA2673119A1 (en) | 2008-06-26 |
| JP2010513558A (ja) | 2010-04-30 |
| KR20090090395A (ko) | 2009-08-25 |
| US20100093711A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006630A (es) | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. | |
| MX2009006481A (es) | Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona. | |
| WO2007139992A3 (en) | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS | |
| MY148634A (en) | Pyridazinone derivatives | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
| MY148851A (en) | Dihydropyridine derivatives as useful as protein kinase inhibitors | |
| GEP20125537B (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| WO2008107478A8 (en) | Quinolinone derivatives as parp and tank inhibitors | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
| MX2009003834A (es) | Derivados de pirrolidina como inhibidores de iap. | |
| WO2008077555A3 (en) | Substituted isoquinolines and their use as rho-kinase inhibitors | |
| WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
| EA201000100A1 (ru) | Гетероциклические соединения, полезные в качестве ингибиторов mk2 | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| WO2008033562A3 (en) | Kinase inhibitor compounds | |
| MX2012002752A (es) | Compuestos de heteroarilo como inhibidores de cinasa. | |
| WO2008075172A3 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| UA94129C2 (ru) | Соединения для ингибирования митоза | |
| WO2008022286A3 (en) | Small molecule inhibitors of kynurenine-3-monooxygenase | |
| UA96785C2 (uk) | Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |